General Hospital (GH) in Ernakulam prepares for first heart transplant surgery in May, following successful cardiac care initiatives.

Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $71. The firm said Edwards delivered ...

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Edwards Lifesciences raised 2025 revenue forecast after Q1 results beat EPS estimates and TMTT sales jumped 58% amid strong ...

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Mark Wilterding; Mark Wilterding Senior Vice President, Investor Relations and Treasurer; Edwards Lifesciences Corp. Bernard Zovighian; President, Chief Executive Of ...

Edwards Lifesciences Corp (EW) reports an 8% increase in total sales, raises full-year guidance, and achieves significant ...

Edwards Lifesciences reports 8% Q1 2025 sales growth to $1.41B, driven by TAVR & TMTT. Discover regulatory catalysts & future growth insights.

Edwards Lifesciences Corporation ( NYSE: EW) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - ...

Edwards Lifesciences (NYSE: EW) shares stayed put after hours today on first-quarter results that beat Wall Street ...

Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment. The company has revised ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights. Q1 ...